. 2017 Jul 14;8(1):20–26. doi: 10.1016/j.jpha.2017.07.007

Table 4.

Assessment of stability of ceritinib.

Condition	Ceritinib stability (%)
Bench-top stability (in stock solution) (25 °C)^a	1 µM^c	100 µM^c
1.0 h	103.5	102.0
2.0 h	106.9	108.1
4.0 h	106.2	101.2
6.0 h	108.8	101.1
Bench-top stability (in plasma) (25 °C)^a	0.003 µM^c	1.6 µM^c
1.0 h	100.0	99.3
2.0 h	105.4	101.2
4.0 h	102.2	99.3
6.0 h	104.3	99.5
Auto-sampler stability (in the precipitation solution) (4 °C)^a	0.003 µM^c	1.6 µM^c
1.0 h	103.5	100.0
3.0 h	104.7	100.2
6.0 h	101.2	100.3
9.0 h	100.0	100.5
Freeze-thaw stability (in plasma) (− 80 °C)^b	0.003 µM^c	1.6 µM^c
Cycle 1	107.1	99.0
Cycle 2	105.9	96.8
Cycle 3	104.7	98.7
Long-term stability (in plasma) (− 80 °C)^b	0.003 µM^c	1.6 µM^c
1 months	105.9	89.7
5 months	108.2	80.7
8 months	101.2	83.6

Stability data is expressed as the mean percentage of the peak area determined at certain time relative to that at time zero.

Stability data is expressed as the mean percentage of the analyte concentration determined at certain time point relative to the nominal concentration (%).

Each concentration at each time point was assessed in triplicate.